Skip to main content
. Author manuscript; available in PMC: 2018 Apr 13.
Published in final edited form as: Exp Parasitol. 2015 Mar 24;153:139–150. doi: 10.1016/j.exppara.2015.03.012

Figure 6. Development of an allergy preventative based on SG-sCD23.

Figure 6

A. Western blot of recombinant (r) sCD23. Native rSG-sCD23 is shown on the left and rSG-sCD23-A/G on the right. B. rSG-sCD23-A/G has increased ability to block IgE from binding to FcεRI+ THP-1 cells. Full-length, commercially available rsCD23 is used for comparison (n=4 separate experiments; P<0.05). C. The effectiveness of rSG-sCD23-A/G is similar to Omalizumab (Xolair) in preventing IgE from binding to IL-4-treated CD23+ tonsil MC measured by MFI (C) and percent positive (E); (n=4 tonsils; P<0.05 compared to IgE). D. rSG-sCD23-A/G expressed as a fusion protein with human IgG4 retained the ability to prevent IgE from binding to CD23+ tonsil cells (n=4 tonsils; P<0.05 compared to IgE.)